LXRX Stock Forecast: Lexicon Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Lexicon Pharmaceuticals, Inc. is $4.7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 69 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Lexicon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (90): The business earns solid, repeatable profits on what it owns.
Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LXRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LXRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | Citigroup | Maintains | Buy | $3.10 → $3.40 |
| 28 Sept 2026 | Cantor Fitzgerald | Initiates | Overweight | $8.00 |
| 11 May 2026 | Citigroup | Maintains | Buy | $2.30 → $3.10 |
| 23 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Mar 2026 | Citigroup | Maintains | Buy | — |
| 5 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Aug 2025 | Citigroup | Maintains | Buy | — |
| 24 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | Needham | Reiterates | Hold | — |
| 7 Mar 2025 | Piper Sandler | Maintains | Overweight | — |
| 4 Mar 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | Needham | Reiterates | Hold | — |
| 29 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 Jan 2025 | Needham | Reiterates | Hold | — |
| 23 Dec 2024 | Needham | Reiterates | Hold | — |
| 25 Nov 2024 | Needham | Reiterates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LXRX.
This page is one stock. Monday covers all of them.
LXRX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LXRX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Lexicon Pharmaceuticals, Inc. returned +15.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
LXRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 19.4×
- Price / book
- 4.6×
- EV / EBITDA
- —
Cheaper than 8% of US stocks
Cheaper than 20% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 94.4%
- Operating margin
- —
- Net margin
- —
Higher than 98% of US stocks
- Return on equity
- −43.9%
- Return on assets
- −15.9%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lexicon Pharmaceuticals, Inc. has a market value of $743.5M and an enterprise value of $619.9M.
Revenue in the twelve months to 30 June 2026: $41.5M. The latest quarter shrank 97.6% year on year.
Net income over the same four quarters: −$61.1M, a −147.4% net margin.
Diluted earnings per share, trailing twelve months: −$0.15.
Free cash flow in the twelve months to 30 June 2026: −$65.0M.
Lexicon Pharmaceuticals, Inc. employs 81 people — $512K of revenue per employee.
Data provided by Twelve Data
LXRX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LXRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Lexicon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LXRX
What is the LXRX stock price forecast for 2026-2027?
The median 12-month analyst price target for Lexicon Pharmaceuticals, Inc. is $4.7, with estimates ranging from $1.69 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LXRX stock a buy right now?
Of the 6 analysts covering Lexicon Pharmaceuticals, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexicon Pharmaceuticals, Inc. 69 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LXRX?
As at 21 Nov 2026, Lexicon Pharmaceuticals, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).
Will LXRX stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $4.7, and Ticker Nerd's factor model ranks Lexicon Pharmaceuticals, Inc. 69 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LXRX stock forecast for 2030?
No analyst covering Lexicon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LXRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.69 to $8 over the next 12 months.
How has LXRX stock performed over the past year?
Lexicon Pharmaceuticals, Inc. returned +15.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Lexicon Pharmaceuticals, Inc. do?
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. The company’s current portfolio centers on therapies for cardiometabolic disorders, neuropathic pain, and other chronic conditions, with products and candidates spanning commercial, clinical, and preclinical stages.
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. The company’s current portfolio centers on therapies for cardiometabolic disorders, neuropathic pain, and other chronic conditions, with products and candidates spanning commercial, clinical, and preclinical stages. Its marketed medicine INPEFA (sotagliflozin) is used in cardiometabolic care, while development programs include pilavapadin for neuropathic pain and LX9851 for obesity and related metabolic disorders. Lexicon Pharmaceuticals also applies its gene-science and target-biology expertise to advance drug candidates aimed at genetically defined pathways, reflecting a research-driven model that links discovery with commercialization. Headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals serves the specialty pharmaceutical market through a focused pipeline designed for patients with serious, long-term medical needs.
CEO Dr. Michael S. Exton Ph.D. · 81 employees · United States · https://www.lexpharma.com